ReviewAngewandte Chemie (International ed. in English)2026
Site-Specific Protein Bioconjugation Through Cellular Incorporation of Noncanonical Amino Acids.
Review in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Traditional methods for protein bioconjugation, such as those targeting canonical amino acid residues, often suffer from a lack of site-specificity, yielding heterogeneous conjugates. Genetic code expansion (GCE) technology offers an exciting alternative, enabling site-specific incorporation of noncanonical amino acids (ncAAs) bearing uniquely reactive chemical groups into recombinant proteins expressed in diverse host cells. The resulting proteins can be chemoselectively labeled at the installed ncAA residues under mild conditions to generate homogeneous, site-specific conjugates. In addition to offering site-specificity, the small size of the ncAA residues minimizes the risk of structural perturbation, allowing access to many more internal sites in proteins relative to alternative site-specific protein labeling approaches that require genetically encoded peptide and protein tags. Remarkable progress has been made in recent years, from improving the efficiency of ncAA incorporation at single or multiple sites, to expanding the palette of available chemistries, and applying this technology for both scientific discovery and the development of potential therapeutics and diagnostics. This review examines these advances and provides our perspectives on current challenges and future opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.